JAK3 and Hodgkins lymphoma: SOCS1 inactivating mutations or deletions have been previously shown to abolish control of phospho-JAK2 or phospho-STAT5 signaling in primary mediastinal B-cell and Hodgkin lymphomas [16, 17], recalling the picture described here for JAK3 and SOCS1.